Adherence to Background Antipsychotic and Pimavanserin in Patients with Schizophrenia: Post Hoc Analyses from the ENHANCE and ADVANCE Studies
Dragana Bugarski-Kirola,Brandon Abbs,Ramzey Odetalla,I-Yuan Liu,Mona Darwish,Daryl DeKarske
DOI: https://doi.org/10.2147/ppa.s436041
2024-01-20
Patient Preference and Adherence
Abstract:Dragana Bugarski-Kirola, 1, 2 Brandon Abbs, 2 Ramzey Odetalla, 2 I-Yuan Liu, 2 Mona Darwish, 2 Daryl DeKarske 3 1 Acadia Pharmaceuticals GmbH, Basel, Switzerland; 2 Acadia Pharmaceuticals Inc, Princeton, NJ, USA; 3 Acadia Pharmaceuticals Inc, San Diego, CA, USA Correspondence: Dragana Bugarski-Kirola, Acadia Pharmaceuticals GmbH, Barfüẞerplatz 3, Basel, Switzerland, 4051, Tel +41798658317, Email Background: In patients with schizophrenia, study design to optimize adherence and objective measurement of adherence is critical for interpreting results. Two randomized, double-blind studies evaluating adjunctive pimavanserin in patients with schizophrenia who received stable antipsychotic treatment included measures to encourage and assess treatment adherence. Objective: This post hoc analysis evaluated adherence levels achieved in the Phase III ENHANCE study (NCT02970292) and the Phase II ADVANCE study (NCT02970305). Methods: Blood levels of participants receiving adjunctive treatment with pimavanserin or placebo added to their ongoing antipsychotic medication were tested and evaluated regularly throughout both studies. For both the background antipsychotic and pimavanserin, treatment adherence was defined as a blood sample test result above the lower limit of quantification. Results: Overall, 392 of 633 screened patients and 403 of 608 screened patients were in the safety populations in ENHANCE and ADVANCE, respectively. In ENHANCE, at weeks 1, 3, and 6/early termination (ET), the adherence rates remained ≥ 95.1% for the background antipsychotic in both pimavanserin and placebo treatment groups and ≥ 96.8% for pimavanserin. In ADVANCE, high adherence rates (≥ 90.6%) with the background antipsychotic (for both treatment groups) and pimavanserin (≥ 95.0%) were observed at weeks 2, 8, 14, and 26/ET. Conclusion: Rigorous screening was performed to exclude patients not adherent to their background antipsychotic before enrollment and to pimavanserin during study visits by using regular blood sampling. Mandatory caregiver participation further supported adherence to study treatment and procedures. These efforts may have contributed to the high levels of adherence to both background antipsychotic and pimavanserin reported in ENHANCE and ADVANCE. Keywords: adjunctive therapy, treatment compliance, pharmacokinetic drug levels, blood sampling, negative symptoms, caregiver participation Many individuals with schizophrenia experience an inadequate response to antipsychotic treatment, 1 which may reflect subtherapeutic exposure to the drug or medication ineffectiveness. Treatment nonadherence should be considered first in patients who experience inadequate treatment response despite therapeutic doses by evaluating subtherapeutic antipsychotic blood levels. 2 Patients who do not adhere to their prescribed regimen accrue higher costs of care and experience worse clinical outcomes compared with patients who adhere to their prescribed regimen. 3 Failure to achieve therapeutic levels of the study treatment as a result of poor adherence may also complicate the interpretation of clinical study outcomes 4 and hinder the development of a potentially effective treatment. Confirming adherence among patients in a clinical study is necessary to ensure that the results of the study are an accurate reflection of the therapeutic potential of the agent under investigation. 2 Moreover, this practice is consistent with US Food and Drug Administration guidance on enrichment strategies to support approval of human drugs and biologic products, in which identifying and selecting patients likely to adhere to treatment is a "useful and generally accepted" strategy to decrease variability. 5 Conversely, high rates of adherence in a clinical study can complement positive efficacy and safety results, providing additional evidence that the investigational agent can improve a patient's symptoms without burdensome or treatment-limiting adverse effects. Therefore, it is important to test for adherence when determining eligibility for a study, measure adherence during the study, and review the adherence results after study completion, regardless of the study outcome. Rigorous assessment of adherence through pharmacokinetic levels of exposure was part of the study design of 2 randomized, double-blind, placebo-controlled studies of pimavanserin in patients with schizophrenia who had been stable while receiving current antipsychotic treatment: ENHANCE (NCT02970292) and ADVANCE (NCT02970305). The phase III ENHANCE study evaluated the efficacy and safety of adjunctive pimavanserin in adult patients -Abstract Truncated-
medicine, general & internal